Real-world study confirms long-term safety of Enjaymo for CAD
Enjaymo (sutimlimab-jome) remains safe to use over the long term, according to new real-world data from adults with primary or secondary cold agglutinin disease (CAD) who have been taking the approved medication for an average of more than two years. The data come from CADENCE (NCT05791708), an…